RELAFEN
LOE ApproachingNDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RELAFEN by GSK is clinical pharmacology nabumetone is a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. First approved in 1991.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELAFEN (nabumetone) is an oral NSAID that exhibits anti-inflammatory, analgesic, and antipyretic properties through inhibition of prostaglandin synthesis. It is a prodrug that undergoes hepatic conversion to its active metabolite 6MNA, which is a potent inhibitor of prostaglandin synthesis. The drug is indicated for inflammatory and pain conditions where NSAID therapy is appropriate.
LOE Approaching
Product approaching loss of exclusivity with declining commercial opportunity; brand team likely in maintenance or transition mode.
Mechanism of Action
CLINICAL PHARMACOLOGY Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. As with other non-steroidal anti-inflammatory agents, its mode of action is not known; however, the ability to inhibit…
Worked on RELAFEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.